CA2597101A1 - Utilisation de bloqueurs de canaux sodiques et de leurs analogues pour traiter la dependance a la nicotine - Google Patents

Utilisation de bloqueurs de canaux sodiques et de leurs analogues pour traiter la dependance a la nicotine Download PDF

Info

Publication number
CA2597101A1
CA2597101A1 CA002597101A CA2597101A CA2597101A1 CA 2597101 A1 CA2597101 A1 CA 2597101A1 CA 002597101 A CA002597101 A CA 002597101A CA 2597101 A CA2597101 A CA 2597101A CA 2597101 A1 CA2597101 A1 CA 2597101A1
Authority
CA
Canada
Prior art keywords
nicotine
diastereomers
derivatives
ttx
tetrodotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002597101A
Other languages
English (en)
Inventor
Helmut Henrich Buschmann
Antonio Farre Gomis
Jose Miguel Vela Hernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wex Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05384001A external-priority patent/EP1690541A1/fr
Priority claimed from EP05384002A external-priority patent/EP1714655A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2597101A1 publication Critical patent/CA2597101A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002597101A 2005-02-11 2006-02-10 Utilisation de bloqueurs de canaux sodiques et de leurs analogues pour traiter la dependance a la nicotine Abandoned CA2597101A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05384001.3 2005-02-11
EP05384001A EP1690541A1 (fr) 2005-02-11 2005-02-11 Utilisation d'un inhibiteur de canaux sodiques et leur analogues pour le traitement de la dépendance à la nicotine
EP05384002A EP1714655A1 (fr) 2005-04-22 2005-04-22 Utilisation d'un inhibiteur de canaux sodiques et leur analogues pour le traitement de la dépendance à la nicotine.
EP05384002.1 2005-04-22
PCT/EP2006/001322 WO2006084765A1 (fr) 2005-02-11 2006-02-10 Utilisation de bloqueurs de canaux sodiques et de leurs analogues pour traiter la dependance a la nicotine

Publications (1)

Publication Number Publication Date
CA2597101A1 true CA2597101A1 (fr) 2006-08-17

Family

ID=36636342

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002597101A Abandoned CA2597101A1 (fr) 2005-02-11 2006-02-10 Utilisation de bloqueurs de canaux sodiques et de leurs analogues pour traiter la dependance a la nicotine

Country Status (6)

Country Link
EP (1) EP1853268A1 (fr)
AR (1) AR053811A1 (fr)
CA (1) CA2597101A1 (fr)
PE (1) PE20061036A1 (fr)
TW (1) TW200640463A (fr)
WO (1) WO2006084765A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201602576D0 (en) 2016-02-12 2016-03-30 Bergen Teknologioverforing As Process

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024903A1 (fr) * 1994-03-17 1995-09-21 Nanning Maple Leaf Pharmaceutical Co., Ltd. Application de composes de quinazoline amino-hydrogenes et de leurs derives au sevrage des toxicomanes
CN1284536C (zh) * 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用

Also Published As

Publication number Publication date
AR053811A1 (es) 2007-05-23
WO2006084765A1 (fr) 2006-08-17
PE20061036A1 (es) 2006-11-24
EP1853268A1 (fr) 2007-11-14
TW200640463A (en) 2006-12-01

Similar Documents

Publication Publication Date Title
IL266674B1 (en) Preparations, devices and methods for the use of nalamfen and dodecyl maltozide through the nose for the treatment of an opioid overdose.
DK2574167T3 (en) LIQUID NOSE SPRAY CONTAINING low-dose naltrexone
HU206042B (en) Process for producing pharmaceutical compositions comprising indole-3-carboxylic acid-endo-8-methyl-8-azabicyclo/3.2.1./oct-3-yl ester and/or 1,2,3-9-tetrahydro-9-methyl-3-(2-methyl-1h-imidazol-1-yl)-methyl-4h-carbazol-4-one, with an activity preventing or reducing opiate-, alcohol- and nicotine-dependence
US20180092839A1 (en) Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
US20120232136A1 (en) Substance with sedative effect
AU2005287511A1 (en) Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
AU2021204517B2 (en) Combination of opioids and n-acylethanolamines
US20100075992A1 (en) Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain
SK287180B6 (sk) Kombinácia účinných látok na medikamentóznu terapiu návykových alebo omamných prostriedkov
PL196334B1 (pl) Zastosowanie agonistów receptorów GABA B i ich farmaceutycznie dopuszczalnych pochodnych w terapii abstynencji nikotynowej u uzależnionych od nikotyny pacjentów
TW457087B (en) Pharmaceutical composition for inhibiting dependency and tolerance developed by narcotic analgesic agent
CA2597101A1 (fr) Utilisation de bloqueurs de canaux sodiques et de leurs analogues pour traiter la dependance a la nicotine
EP1690541A1 (fr) Utilisation d'un inhibiteur de canaux sodiques et leur analogues pour le traitement de la dépendance à la nicotine
EP1714655A1 (fr) Utilisation d'un inhibiteur de canaux sodiques et leur analogues pour le traitement de la dépendance à la nicotine.
EP1702627A1 (fr) Combinaison analgésique comprenant des inhibiteurs de canaux sodiques et des antagonistes d'opioïdes
KR100736016B1 (ko) 알코올 및/또는 담배 소비 감소를 위한 의약 및 방법
ZA200507213B (en) Combination of desoxypeganine and mecamylamine forthe treatment of alcohol abuse
EA007628B1 (ru) Сочетание действующих веществ для фармакологического лечения никотиновой зависимости
US8106074B2 (en) Pyridin-2-yl-methylamine derivatives for treating opiate dependence

Legal Events

Date Code Title Description
FZDE Dead